 HYDERABAD, India PRINCETON, N.J.--BUSINESS WIRE--Dr. Reddys Laboratories Ltd. BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as Dr. Reddys today announced the launch of Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU carmustine for injection approved by the U.S. Food and Drug Administration USFDA. The BiCNU brand and generic market had U.S. sales of approximately 19.4 million MAT for the 